reviewed april 2026|next review october 2026|88 physicians psi has verified|53974 published studies
AHK-Cu (Copper Tripeptide)
Alanyl-histidyl-lysine copper complex (AHK-Cu) is a copper-binding tripeptide structurally related to GHK-Cu with an alanine substitution at the first position, studied primarily for hair growth stimulation through dermal papilla cell proliferation in cell culture.
Evidence landscape: 53974 published studies
53,974 published items (broad copper peptide query). 38 human studies and 103 animal studies.
- 38 Human
- 103 Animal
- 59 Reviews
- 53774 Other research
AHK-Cu replaces glycine (G) with alanine (A) at the first position compared to GHK-Cu. The His-Lys copper-binding motif is preserved. Whether this substitution confers any biological advantage is not established.
Marketed and studied primarily for hair growth stimulation. Evidence is limited to dermal papilla cell proliferation in cell culture. No clinical trials of any kind.
GHK-Cu has 186 published studies. AHK-Cu has a fraction of that. No head-to-head comparisons between the two compounds have been published.
PSI Assessment
AHK-Cu is a copper-binding tripeptide marketed primarily for hair growth. It shares the His-Lys copper-binding motif with GHK-Cu but substitutes alanine for glycine at the first position. The hair growth research is limited to cell culture studies showing dermal papilla cell proliferation. No clinical trials of any kind have been conducted. GHK-Cu has 186 published studies; AHK-Cu has a fraction of that evidence base. Whether the alanine substitution confers any advantage over GHK-Cu for hair or skin applications has not been tested in comparative studies.
Alanine substitution at the first position compared to GHK-Cu. Hair follicle research focus. Evidence limited to cell culture studies.
AHK-Cu (Ala-His-Lys + Cu2+) is a copper-binding tripeptide structurally related to GHK-Cu. The alanine substitution at the first position differentiates it from the glycine in GHK-Cu while preserving the histidine-lysine copper-binding motif. It has been studied primarily for hair growth stimulation, with cell culture data showing increased dermal papilla cell proliferation. No clinical trials have been conducted. The evidence base is a small fraction of what exists for GHK-Cu, the research benchmark in the copper peptide family.
What the evidence supports
AHK-Cu promotes dermal papilla cell proliferation in cell culture studies. The copper-binding tripeptide structure is characterized. The alanine substitution at the first position differentiates it from GHK-Cu.
What is not yet established
Whether AHK-Cu produces hair growth in humans. Clinical trials of any kind. Whether the alanine substitution confers any advantage over GHK-Cu for hair or skin applications. Comparative studies against GHK-Cu.
Research Evidence
The findings below cover the hair growth cell culture data, the structural relationship to GHK-Cu, and the evidence depth disparity.
Evidence by condition
Evidence dimensions across AHK-Cu conditions. All hair growth data is from cell culture. No clinical trials for any indication.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Hair Growth | ||||
| Skin Health | ||||
| Copper Delivery |
Cell culture studies show AHK-Cu promotes dermal papilla cell proliferation and stimulates VEGF expression around hair follicle models.
Cell culture proliferation does not predict clinical hair growth. No in vivo studies or clinical trials have been conducted. Dermal papilla cell stimulation is a necessary but insufficient condition for hair growth in living systems.
The alanine substitution at the first position preserves the His-Lys copper-binding motif. AHK-Cu coordinates Cu(II) similarly to GHK-Cu.
Whether the alanine substitution confers any biological advantage over glycine (GHK-Cu) has not been tested in comparative studies. The marketing differentiation is not supported by comparative evidence.
GHK-Cu has 186 published studies and documented modulation of over 4,000 genes. AHK-Cu has a fraction of that evidence base with no head-to-head comparisons published.
The evidence depth disparity is the central consideration. GHK-Cu is the research benchmark for the copper peptide family. AHK-Cu is a commercially differentiated variant without comparative validation.
38 Human|103 Animal|59 Reviews
View all 53974 indexed studiesHow AHK-Cu (Copper Tripeptide) Works
AHK-Cu (Ala-His-Lys copper complex) is a copper-binding tripeptide that delivers Cu(II) to tissues through the same histidine-lysine binding motif as GHK-Cu, with an alanine substitution at the first position.
Delivers copper to skin and hair follicles to support collagen and potentially stimulate hair growth.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Ala-His-Lys coordinates Cu(II). Proposed to stimulate dermal papilla cells.
What is AHK-Cu (Copper Tripeptide) being studied for?
Researchers are studying AHK-Cu (Copper Tripeptide) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for AHK-Cu (Copper Tripeptide) overall. This means a compound can have human studies for one condition but only animal data for another.
Hair Growth
·PreclinicalCell culture studies show dermal papilla cell proliferation and VEGF upregulation with AHK-Cu treatment.
Limitations: All data is from cell culture. No animal studies or clinical trials. Cell proliferation in culture does not predict clinical hair growth.
Skin Health
·PreclinicalAs a copper-binding peptide, AHK-Cu is marketed for skin health based on the broader copper peptide class evidence.
Limitations: No skin-specific studies for AHK-Cu. Evidence is inherited from the copper peptide class, primarily from GHK-Cu research.
Copper Delivery
·PreclinicalAHK-Cu coordinates Cu(II) through the His-Lys motif, functioning as a copper delivery vehicle to tissues.
Limitations: Copper-binding is characterized biochemically. Whether AHK-Cu delivers copper more effectively than GHK-Cu for any specific application is not established.
Safety and Regulatory Status
FDA Status: Not a regulated pharmaceutical. Used as a cosmetic ingredient in hair care products.
Availability: Available in over-the-counter hair care and skincare products containing copper peptides.
Class context: Copper-binding tripeptide in the GHK-Cu family. Alanine substitution variant. Marketed primarily for hair growth applications.
Topical copper peptide with excellent safety profile. No systemic effects reported. As a cosmetic ingredient, the concern is efficacy rather than safety.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a AHK-Cu (Copper Tripeptide) discussion.
Comparison and Related Research
AHK-Cu is most often compared with GHK-Cu (research benchmark, broader evidence), DAHK (copper transport peptide), and minoxidil (FDA-approved hair growth treatment).
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Study demonstrating that copper tripeptides including AHK-Cu promote dermal papilla cell proliferation and hair follicle growth in cell culture models. The research showed increased VEGF expression around hair follicle structures with copper peptide treatment.Pyo HK et al., 2007 in J Pept Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.